References in periodicals archive ?
Heron) announced that it has reached its enrollment target in MAGIC (Modified Absorption Granisetron In the Prevention of Chemotherapy induced nausea and vomiting (CINV)).
More recently, a pharmacotherapy trial investigated the use of granisetron to treat sexual dysfunction associated with antidepressant use in female patients diagnosed with depression.
APF530 contains the 5-HT3 antagonist granisetron formulated in the Company's proprietary Biochronomer[TM] drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
The recent European approval of Archimedes' innovative fentanyl pectin nasal spray product for of breakthrough cancer pain (PecFent) is one example of a product specifically designed for purpose and there are numerous other nasal drugs in clinical development at Archimedes and elsewhere, including granisetron (nausea/vomiting), diazepam and midazolam (seizures), testosterone (hypogonadism) and apomorphine (Parkinson's disease).
Hence we have performed a double blind, randomized controlled trial to compare the relative efficacies of ondansetron, granisetron and palonosetron for both acute and delayed onset emesis, in moderately and highly emetogenic chemotherapy against their respective prices in Indian market.
Granisetron transdermal system (Sancuso[R]) is the first transdermal medication indicated for use in chemotherapy-induced nausea and vomiting.
and granisetron (Kytril, marketed by Hoffmann-La Roche Inc.
3] receptor antagonists ondansetron or granisetron to women undergoing cesarean delivery with neuraxial anesthesia significantly reduces intraoperative and postoperative nausea and vomiting, compared with placebo, according to a meta-analysis of nine randomized, double-blind trials.
5 mg injections for the study free of charge and Roche Laboratories (Nutley, NJ) provided a $600 grant to cover the cost of granisetron for the study.
Tokyo, Japan, May 26, 2006 - (JCN) - Translational Research, a subsidiary of Shin Nippon Biomedical Laboratories, has developed an intranasal formulation of granisetron, an agent with antiemetic efficacy.
3] receptor antagonists, such as ondansetron and granisetron, in the late '80s and early '90s, in recent years new compounds have been made available for preventing CINV, including palonosetron.
In particular, there are no data on the effect of granisetron on postoperative shivering in the paediatric patient population.